Loading
BioCardia, Inc. Stock: price and insider trades · United States
1 insider bought €13k of shares over the last 90 days, the latest filed 30 Sept 2026.
BioCardia, Inc.: what insiders have been doing
This page follows insider dealings at BioCardia, Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. In the past year (18 October 2025 to 18 October 2026), 37 filings came from 4 insiders.
Every open-market trade in the period is a purchase: 28 purchases worth €45k, from 2 insiders, and not a single sale. The totals do not cover 5 filings with an undisclosed amount. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Biggest ticket of the year: €4,782, bought by Altman Peter and made public on 4 February 2026. Those buying include 1 senior executive and 1 chief executive.
With 37 filings in twelve months, the company is more active than the median of 19 filings across the 5,812 companies we follow on the same exchange. Since 2021, the database holds 81 purchases and 2 sales by insiders of the company. The 10-K for the year ended 31 December 2025 shows -8.2 m USD of net income.
The clock since the last published purchase (30 September 2026) now reads 18 days. Typically, a trade is published a median of 2 days after it takes place. For comparison, the SEC allows two business days to file a Form 4.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Cytosorbents Corp. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
129
Thresholds
n/a
Buy Volume
€3M
81 ops. · all time
Sell Volume
€57,589
2 ops. · all time
Who traded when
BuySalePeter Altman48 buys
Simon H. Stertzer7 buys
Andrew Scott Blank3 buys
David McClung2 buys
Bill Facteau1 buy
Edward M. Gillis1 sale
+1 other insider
Since the insiders bought
- -15.3%Entry US$1.11 · Close 15 Oct 2026 US$0.94
- -13.8%Entry US$1.09 · Close 15 Oct 2026 US$0.94
- -27.7%Entry US$1.48 · Close at T+365 US$1.07
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$0.99
Analyst consensus
2 analysts1.00/5
US$6.00Target US$15.50(+1466%)US$25.00
Income statement
Gross profitUS$1M
EBITDA-US$8.3M
Net income-US$8.2M0.0% margin
Valuation
PER (forward)-1.7x
P/Book5.5x
Beta0.62
Balance sheet & cash
Market capUS$15M
Total debtUS$528k
Free Cash Flow-US$7.4M
Debt / Equity11%
Profitability & ownership
ROE-1803.2%
ROA-135.0%
% insiders17.9%
% institutions14.8%
Last declaration on 30 September 2026
Declarations129 total
1,000 shares@ US$1.030.0066% mcap0.1% of flowCommon StockSEC:0001437749-26-031638:0
Canonical exit: 28 Dec 2026 (T+90)
1,900 shares@ US$1.050.012% mcap0.2% of flowCommon StockSEC:0001437749-26-031093:0
Canonical exit: 22 Dec 2026 (T+90)
800 shares@ US$1.090.0054% mcap0.1% of flowCommon StockSEC:0001437749-26-029732:0
Canonical exit: 2 Dec 2026 (T+90)
5,400 shares@ US$0.930.031% mcap0.4% of flowCommon StockSEC:0001437749-26-028307:0
Canonical exit: 15 Nov 2026 (T+90)
1,900 shares@ US$0.920.011% mcap0.1% of flowCommon StockSEC:0001437749-26-027743:0
Canonical exit: 11 Nov 2026 (T+90)
5,000 shares@ US$0.780.025% mcap0.3% of flowCommon StockSEC:0001437749-26-024925:0
Canonical exit: 27 Oct 2026 (T+90)
500 shares@ US$0.830.0026% mcap0.0% of flowCommon StockSEC:0001437749-26-023868:0
Canonical exit: 15 Oct 2026 (T+90)
2,800 shares@ US$0.880.015% mcap0.2% of flowCommon StockSEC:0001437749-26-023637:0
Canonical exit: 12 Oct 2026 (T+90)
1,500 shares@ US$0.860.0081% mcap0.1% of flowCommon StockSEC:0001437749-26-023637:1
Canonical exit: 13 Oct 2026 (T+90)
5,500 shares@ US$0.970.033% mcap0.4% of flowCommon StockSEC:0001437749-26-023365:0
Canonical exit: 6 Oct 2026 (T+90)
1,000 shares@ US$0.900.0056% mcap0.1% of flowCommon StockSEC:0001437749-26-023365:1
Canonical exit: 7 Oct 2026 (T+90)
1,000 shares@ US$0.940.0059% mcap0.1% of flowCommon StockSEC:0001437749-26-023365:2
Canonical exit: 8 Oct 2026 (T+90)
5,400 shares@ US$0.96450.033% mcap0.4% of flowCommon StockSEC:0001437749-26-023016:0
Canonical exit: 6 Oct 2026 (T+90)
23,125 shares@ US$1.240.18% mcap5.7% of flowCommon StockSEC:0001437749-26-022968:0
54,606 shares@ US$1.240.42% mcap5.3% of flowCommon StockSEC:0001437749-26-022969:0
17,269 shares@ US$1.240.13% mcap7.5% of flowCommon StockSEC:0001437749-26-022967:0
110,625 sharesCommon StockSEC:0001437749-26-022365:0
39,521 sharesCommon StockSEC:0001437749-26-022363:0
60,483 sharesCommon StockSEC:0001437749-26-022364:0
70,200 sharesCommon StockSEC:0001437749-26-021597:0
Canonical exit: 20 Sept 2026 (T+90)
39,000 sharesCommon StockSEC:0001437749-26-021597:1
Canonical exit: 21 Sept 2026 (T+90)
1,500 sharesCommon StockSEC:0001437749-26-021216:0
Canonical exit: 15 Sept 2026 (T+90)
800 sharesCommon StockSEC:0001437749-26-021216:1
Canonical exit: 16 Sept 2026 (T+90)
5,000 sharesCommon StockSEC:0001437749-26-020044:0
Canonical exit: 7 Sept 2026 (T+90)
1,500 shares@ US$0.920.011% mcap0.1% of flowCommon StockSEC:0001437749-26-018125:1
Canonical exit: 18 Aug 2026 (T+90)
25 of 129 declarations
About BioCardia, Inc.
BioCardia, Inc. (ticker: BCDA) is a U.S.-based biotechnology company listed on the NASDAQ in the United States, focused on cell therapies and related delivery systems for cardiovascular and pulmonary diseases with substantial unmet medical need. Headquartered in Sunnyvale, California, the company operates in a single business segment and is best described as a clinical-stage regenerative medicine platform rather than a commercial pharmaceutical manufacturer. Its strategy centers on developing cellular and cell-derived therapeutics, combined with proprietary minimally invasive delivery and navigation technologies designed to place treatment directly in the target tissue. ([sec.gov](https://www.sec.gov/Archives/edgar/data/925741/000143774925009397/bcda20241231_10k.htm?utm_source=openai))
BioCardia’s history is rooted in regenerative medicine and cardiac intervention. Over time, the company built a portfolio around cell therapy programs and catheter-based delivery tools, and later adopted the BioCardia name following a reverse merger transaction. The business remains highly concentrated in the U.S., with core operations in Sunnyvale and a lean organization that includes clinical development, product development, regulatory, manufacturing, quality, finance, administration, and commercial support functions. ([sec.gov](https://www.sec.gov/Archives/edgar/data/925741/000143774925009397/bcda20241231_10k.htm?utm_source=openai))
Read moreShow less
The company’s core pipeline is led by CardiAMP®, an autologous mononuclear cell therapy intended for ischemic heart failure with reduced ejection fraction. BioCardia also develops CardiALLO™, an investigational allogeneic “off-the-shelf” cell therapy platform, as well as the Helix™ biotherapeutic delivery system, a transendocardial catheter platform used to deliver therapeutic or diagnostic agents to the heart. In addition, the company’s Morph® DNA steerable introducer products support navigation and positioning during procedures. This integrated product stack is a key differentiator: BioCardia is not only developing a therapy, but also the procedural infrastructure needed to administer it. ([biocardia.com](https://www.biocardia.com/about-us/about-biocardia/id/1008?utm_source=openai))
From a competitive standpoint, BioCardia remains a specialty, development-stage name with limited commercial scale and a heavy reliance on clinical, regulatory, and financing milestones. Its target markets include ischemic heart failure and refractory angina, areas where treatment options remain constrained. In 2025 and 2026, the company highlighted late-stage CardiAMP HF data and continued discussions with the FDA and Japan’s PMDA. In March 2026, BioCardia reported that the FDA accepted its Helix pre-submission package, and in May 2026 it stated that the agency had aligned on possible clearance pathways for the delivery system, which could improve regulatory visibility over time. ([globenewswire.com](https://www.globenewswire.com/en/news-release/2025/03/31/3052241/0/en/biocardia-phase-3-cardiamp-hf-trial-of-novel-cardiac-cell-therapy-for-ischemic-heart-failure-shows-increased-survival-decreased-cardiac-events-and-improved-quality-of-life-at-two-y.html?utm_source=openai))
For investors, BioCardia is a high-risk, high-optional interest story: a micro-cap clinical biotherapy company with differentiated technology, a U.S. manufacturing and development base, and meaningful upside tied to trial outcomes, regulatory approvals, and eventual partnering or commercialization opportunities. ([biocardia.com](https://www.biocardia.com/investors/press-releases/id/1037?pressReleaseId=256&utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
